Payment overview · 2025
General Payments
$696.96
39 reported records · 11 companies
Healthcare provider profile · identity verified
Steven J Kulback, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1700890233
Verified facts
What the public records show
CMS Open Payments records show Steven J Kulback, MD received $696.96 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.77 | 26.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.82 | 15.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.02 | 12.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.87 | 12.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.15 | 7.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.76 | 7.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.91 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.83 | 4.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.80 | 3.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.69 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.34 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $696.96 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.91 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.02 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $83.87 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.06 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.06 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $71.99 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.37 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $49.76 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 409 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 80 |
| Simvastatin | Simvastatin | 272 | 84 |
| Omeprazole | Omeprazole | 244 | 79 |
| Losartan Potassium | Losartan Potassium | 221 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 46 |
| Lisinopril | Lisinopril | 146 | 50 |
| Carvedilol | Carvedilol | 142 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 47 |
| Trazodone Hcl | Trazodone Hcl | 139 | 42 |
| Gabapentin | Gabapentin | 133 | 46 |
| Meloxicam | Meloxicam | 122 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 41 |
| Furosemide | Furosemide | 110 | 32 |
| Metformin Hcl Er | Metformin Hcl | 110 | 38 |
| Metformin Hcl | Metformin Hcl | 106 | 40 |
| Donepezil Hcl | Donepezil Hcl | 105 | 25 |
| Potassium Chloride | Potassium Chloride | 98 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 19 |
| Eliquis | Apixaban | 92 | 23 |
| Alendronate Sodium | Alendronate Sodium | 89 | 36 |
| Montelukast Sodium | Montelukast Sodium | 86 | 28 |
| Jardiance | Empagliflozin | 82 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 22 |
| Glimepiride | Glimepiride | 72 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 28 |
| Atenolol | Atenolol | 66 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 22 |
| Buspirone Hcl | Buspirone Hcl | 64 | 20 |
| Celecoxib | Celecoxib | 64 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 29 |
| Benazepril Hcl | Benazepril Hcl | 56 | 19 |
| Memantine Hcl | Memantine Hcl | 56 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 20 |
| Sertraline Hcl | Sertraline Hcl | 54 | 19 |
| Allopurinol | Allopurinol | 52 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 15 |
| Famotidine | Famotidine | 46 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Tramadol Hcl | Tramadol Hcl | 44 | 15 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Finasteride | Finasteride | 42 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 13 |
| Valsartan | Valsartan | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 21 |
| Chlorthalidone | Chlorthalidone | 31 | 13 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Nadolol | Nadolol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $696.96 · 39 records | Novo Nordisk Inc | ABRYSVO, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, VOQUEZNA, Veozah, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error